Dragonfly Therapeutics Appoints Head of Biologics

Dr. Asya Grinberg has been appointed head of biologics at Dragonfly Therapeutics, and joins the senior team. Dr. Grinberg will lead the protein engineering, purification, characterization and structural biology team.
 
Dr. Grinberg joins the company from Acceleron Pharma, where she led a multidisciplinary team in cell biology and protein chemistry. She most recently served as senior director of Cell Biology and Protein Chemistry and has been a strong scientific and strategic driver of internal innovation. Dr. Grinberg's efforts were instrumental to the development of five clinical candidates, including Luspatercept (in Phase III testing) for treatment of beta-thalassemia and MDS.  Dr. Grinberg is the key inventor of the IntelliTrap drug discovery platform targeting the TGF-beta superfamily.
 
"We are thrilled to welcome Dr. Grinberg to Dragonfly," said Dragonfly co-founder and chief executive officer Bill Haney. "Her depth of understanding of protein therapeutics, coupled with her talent for innovation, will accelerate our development of novel cancer therapies, which use Natural Killer cells to both enhance the effectiveness of T cell performance and attack cancer directly."